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Ceramides and glucosylceramides (GCs) have both been
implicated in the development of insulin resistance and
the pathogenesis of metabolic diseases associated with
obesity. Inhibitors of either ceramide or glucosylcera-
mide production enhance insulin signaling in adipocytes
and protect mice from high-fat diet induced-insulin
resistance, diabetes, and hepatic steatosis. Moreover, the
addition of either ceramides or glucosylceramides to
3T3-L1 adipocytes impairs insulin signaling. Since inhi-
bitors of ceramide biosynthesis deplete cells of glucosyl-
ceramides, and since exogenous ceramides can be re-
glucosylated to produce glucosylceramides, it remains a
formal possibility that glucosylated ceramides, and not
ceramides themselves, antagonize insulin action. In the
present work, we present evidence revealing that gluco-
sylceramides and ceramides are independent and separ-
able antagonists of insulin signaling. The conclusion
derives from the fact the two sphingolipids have differ-
ential effects on insulin signaling to Akt/PKB in cultured
myotubes, but have comparable effects on insulin signal-
ing to Akt/PKB in adipocytes. First, though inhibitors of
ceramide biosynthesis prevent the antagonism of insulin
signaling by saturated fatty acids in C2C12 myotubes,
inhibitors of glucosylceramide synthase (GCS) have no
effect. Second, incubation of C2C12 myotubes with exo-
genous ceramides antagonizes insulin signaling, while
the addition of the ganglioside GM3 does not. And
third, adenovirus-mediated overexpression of human
GCS (hGCS) in myotubes protects cells from palmitate-
induced inhibition of insulin signaling. In contrast,
increasing glucosylated ceramide levels in 3T3-L1 adipo-
cytes has profound effects. For example, both GM3
addition or hGCS overexpression downregulates insulin
signaling in that cell type. These observations reveal that
both glucosylceramides only induce insulin resistance in
a subset of cell types, and confirm that both glucosylcer-
amides and ceramides are independent antagonists of
insulin action.
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